SMMT enters the second half of August with an unusual alignment — shorts are covering, options traders are increasingly bullish, and insiders are buying with conviction, all while the Street remains deeply divided on whether Ivonescimab can deliver.
The most striking development this week is the collapse in short positioning. Short interest dropped sharply — down roughly 5% in a single session on August 11 and nearly 4.5% across the week — pulling to 4.75% of the free float, the lowest level in over a month. That unwind follows a multi-week build that pushed SI to around 6% of float in mid-July, making the retreat meaningful. The borrow market is relaxed: cost to borrow runs below 0.62%, barely changed on the week, and availability is healthy at roughly 120% — well above the near-zero extreme recorded earlier in the year, meaning there is no meaningful squeeze pressure in the lending pool. Short sellers appear to be stepping back, not fleeing; the unwind is orderly rather than panicked.
Options positioning reinforces the bullish tilt. Call demand has pushed the put/call ratio to 0.45, nearly 1.5 standard deviations below its 20-day average of 0.51 — the most bullish options skew SMMT has registered in months, sitting close to its 52-week low of 0.42. That reading has drifted steadily lower since mid-July, when the PCR was around 0.55, suggesting a genuine shift in options sentiment rather than a one-day spike. Taken together, the short unwind and the call-heavy options book tell the same story: near-term positioning has turned constructive.
The Street is harder to read. The most recent analyst action — Leerink Partners upgrading from Underperform to Market Perform this morning with a $13 target — captures the tension perfectly: the move is bullish relative to prior positioning, yet the $13 target sits well below the current $15.12 price. That contradiction reflects a broader split. The two remaining Buy-rated analysts (Stifel and Guggenheim) both trimmed targets to $38 after last month's earnings miss, while Bernstein's Underperform initiation in May set a $7.70 target. The consensus lands at Hold, with a mean target around $21 — implying upside from here, but only if the clinical story holds together. The bull case rests on HARMONi-3 completing enrollment and a non-squamous cohort readout in H1 2027; the bear case centres on a history of changing protocols and sparse disclosure on key efficacy metrics. EPS momentum scores rank in the 72nd and 75th percentiles at 30 and 90 days respectively, a sign that estimate revisions have been running positive even as the stock has drifted. The ORTEX short score at 75.5 — near a one-week high — flags elevated short-side risk despite the recent cover.
The ownership picture is impossible to ignore. Chairman and CEO Robert Duggan controls 71.9% of shares outstanding and bought 3.81 million additional shares at $13.12 in June — a $50 million outlay at prices well below current levels. President Mahkam Zanganeh added 100,000 shares the same day, and CFO Manmeet Soni bought twice in the same session. Net insider purchases over the 90-day window reached roughly $52 million on 3.96 million shares. That is a concentrated, coordinated bet by the people closest to the clinical data. State Street added 2.5 million shares in July; BlackRock added 700,000. Neither move is enormous in the context of Duggan's dominance, but the directional consistency across institutional buyers adds texture to the insider story.
The most recent earnings print is worth noting for what it set up. The August 4 report produced a 3.7% next-day gain and a 15.9% five-day move — an unusually strong post-print reaction for a stock with no commercial revenue. The prior event on July 23 did the opposite, falling 7.3% the next day and 8.8% over five days. The pattern is binary and volatile, as expected for a clinical-stage oncology name where each catalyst resets sentiment from scratch. The next earnings event is slated for October 20 — the period between now and then is entirely about clinical newsflow.
The next thing to watch is whether the short interest stabilises at current levels or continues lower. A further unwind toward the 3% range, combined with a PCR holding near 52-week lows, would make the setup more charged heading into any interim HARMONi-3 disclosure.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
